Afternoon trading March 8, page-120

PTX
US FDA Grants Orphan Drug Designation
to PTX-100 for broader TCL indications
Key points
 US FDA grants PTX-100 additional Orphan Drug Designation (ODD) for all T cell
lymphomas
 ODD granted for a broader indication than requested by PTX
 Confers several developmental benefits and 7 years of market exclusivity
 Trial update due shortly